Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

395 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024.
Oizumi S, Takamura K, Harada T, Tachihara M, Morikawa N, Honda R, Watanabe S, Asao T, Kunisaki M, Fukuhara T, Noro R, Kikuchi E, Tsutani Y, Tenma T, Kobayashi K, Dosaka-Akita H; North East Japan Study Group, Hokkaido Lung Cancer Clinical Study Group. Oizumi S, et al. Among authors: morikawa n. Int J Clin Oncol. 2022 Apr;27(4):676-683. doi: 10.1007/s10147-021-02113-5. Epub 2022 Jan 29. Int J Clin Oncol. 2022. PMID: 35092535 Clinical Trial.
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Takashina T, Asahina H, Oizumi S, Yamada N, Harada M, Takamura K, Yokouchi H, Harada T, Honjo O, Ogi T, Morikawa N, Kinoshita I, Honda R, Nakano K, Kanazawa K, Amano T, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Takashina T, et al. Among authors: morikawa n. Int J Clin Oncol. 2018 Dec;23(6):1060-1069. doi: 10.1007/s10147-018-1318-z. Epub 2018 Jul 19. Int J Clin Oncol. 2018. PMID: 30027464 Free article. Clinical Trial.
Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302.
Kawashima Y, Harada T, Fujita Y, Nakagawa T, Watanabe K, Morikawa N, Takamura K, Kanazawa K, Kuda T, Usui K, Sekine A, Inoue A, Sugawara S. Kawashima Y, et al. Among authors: morikawa n. Int J Clin Oncol. 2021 Mar;26(3):515-522. doi: 10.1007/s10147-020-01828-1. Epub 2020 Nov 13. Int J Clin Oncol. 2021. PMID: 33184754 Clinical Trial.
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, Gemma A. Maemondo M, et al. Among authors: morikawa n. J Thorac Oncol. 2012 Sep;7(9):1417-22. doi: 10.1097/JTO.0b013e318260de8b. J Thorac Oncol. 2012. PMID: 22895139 Free article. Clinical Trial.
Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
Kawashima Y, Inoue A, Sugawara S, Oizumi S, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T. Kawashima Y, et al. Among authors: morikawa n. Respir Investig. 2014 May;52(3):190-4. doi: 10.1016/j.resinv.2013.12.005. Epub 2014 Jan 28. Respir Investig. 2014. PMID: 24853020 Clinical Trial.
Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab.
Nihei S, Sato J, Harada T, Kuyama S, Suzuki T, Waga N, Saito Y, Kisara S, Yokota A, Okada K, Tsuchiya M, Terui K, Tadokoro Y, Chiba T, Kudo K, Oizumi S, Inoue A, Morikawa N. Nihei S, et al. Among authors: morikawa n. Cancer Chemother Pharmacol. 2018 Jun;81(6):1051-1059. doi: 10.1007/s00280-018-3580-1. Epub 2018 Apr 12. Cancer Chemother Pharmacol. 2018. PMID: 29651572
Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).
Tanaka H, Hasegawa Y, Fujita Y, Nakamura A, Kikuchi E, Kawai Y, Harada T, Watanabe N, Yokouchi H, Usui K, Saito R, Watanabe H, Masuda T, Fukuhara T, Kudo K, Honda R, Oizimi S, Maemondo M, Inoue A, Morikawa N. Tanaka H, et al. Among authors: morikawa n. Thorac Cancer. 2021 Jul;12(14):2113-2121. doi: 10.1111/1759-7714.14048. Epub 2021 Jun 2. Thorac Cancer. 2021. PMID: 34076966 Free PMC article. Clinical Trial.
Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.
Maemondo M, Inoue A, Sugawara S, Harada T, Minegishi Y, Usui K, Miwa K, Morikawa N, Kambe M, Ube K, Watanabe K, Ishimoto O, Sakakibara T, Gemma A, Nukiwa T. Maemondo M, et al. Among authors: morikawa n. Oncologist. 2014 Apr;19(4):352-3. doi: 10.1634/theoncologist.2013-0411. Epub 2014 Mar 28. Oncologist. 2014. PMID: 24682465 Free PMC article. Clinical Trial.
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y; North-East Japan Study Group. Matsumoto Y, et al. Among authors: morikawa n. Lung Cancer. 2014 Nov;86(2):195-200. doi: 10.1016/j.lungcan.2014.08.019. Epub 2014 Sep 16. Lung Cancer. 2014. PMID: 25249428 Clinical Trial.
395 results